CHARGED ALPHA
Stock Analysis
Stock Library / SMMT
SMMT Unclassified Latest YouTube: Q2 2026 Published 2026-07-25

SMMT

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

Summit Therapeutics (SMMT): Landmark Cancer Data, a $10B Binary — We Say HOLD (~$16)

Published 2026-07-25

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q2 2026
2026-07-25
Podcast available
Yes
Current price
$12.55
-0.68 (-5.14%)
Trailing / Forward P/E
Forward: -10.62x
Market cap / Volume
Volume:
Revenue / Earnings Growth
Earnings: —
Margins
0.0% op
Gross: 0.0% · Net: 0.0%
Balance sheet
6.96x current
Debt / Equity: 3.2
52-week range / Beta
$12.55 - $30.98
Beta: -1.26
Analyst target
$28.01
Upside: 123.2%
Cash / shareholder return
-1.40% FCF yield
Dividend yield: —

Company context

Industry: Biotechnology
Country: United States
Employees:
Price to book: 17.83x
Return on equity: -192.5%
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Price chart

Market context for SMMT

Competitive view

SMMT vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

SMMT latest YouTube video thumbnail YouTube
SMMT
SMMT
Latest video
Q2 2026
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
SS&C Technologies Holdings Inc. latest YouTube video thumbnail YouTube
SS&C Technologies Holdings Inc.
SSNC
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Danaher Corporation latest YouTube video thumbnail YouTube
Danaher Corporation
DHR
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
SMMT
$10.01B
SMMT
SSNC
$18.76B
SS&C Technologies Holdings Inc.
DHR
$139.93B
Danaher Corporation
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
SMMT
SMMT
SSNC
21.6x
SS&C Technologies Holdings Inc.
DHR
35.1x
Danaher Corporation
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
SMMT
-10.6x
SMMT
SSNC
10.1x
SS&C Technologies Holdings Inc.
DHR
21.5x
Danaher Corporation
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
SMMT
SMMT
SSNC
10.3%
SS&C Technologies Holdings Inc.
DHR
5.5%
Danaher Corporation
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
SMMT
SMMT
SSNC
34.7%
SS&C Technologies Holdings Inc.
DHR
59.7%
Danaher Corporation
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
SMMT
0.0%
SMMT
SSNC
24.6%
SS&C Technologies Holdings Inc.
DHR
19.8%
Danaher Corporation
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
SMMT
0.0%
SMMT
SSNC
48.1%
SS&C Technologies Holdings Inc.
DHR
58.8%
Danaher Corporation
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
SMMT
0.0%
SMMT
SSNC
13.2%
SS&C Technologies Holdings Inc.
DHR
15.9%
Danaher Corporation
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
SMMT
-192.5%
SMMT
SSNC
12.6%
SS&C Technologies Holdings Inc.
DHR
7.6%
Danaher Corporation
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
SMMT
-1.4%
SMMT
SSNC
6.9%
SS&C Technologies Holdings Inc.
DHR
3.1%
Danaher Corporation
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
SMMT
3.24x
SMMT
SSNC
115.90x
SS&C Technologies Holdings Inc.
DHR
52.97x
Danaher Corporation
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
SMMT
6.96x
SMMT
SSNC
1.06x
SS&C Technologies Holdings Inc.
DHR
1.65x
Danaher Corporation
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
SMMT
-1.26
SMMT
SSNC
1.11
SS&C Technologies Holdings Inc.
DHR
0.82
Danaher Corporation
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
SMMT
SMMT
SSNC
0.7%
SS&C Technologies Holdings Inc.
DHR
0.7%
Danaher Corporation
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
SMMT
123.2%
SMMT
SSNC
18.5%
SS&C Technologies Holdings Inc.
DHR
14.3%
Danaher Corporation

Related research

Non-quarter videos featuring SMMT

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-24

Summit Therapeutics (SMMT): HOLD — Landmark Data, $10B Binary #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for SMMT

Each row is one earnings episode with every verified platform link available.

Q2 2026
Episode live
2026-07-25
Published youtube podcast complete
Summit Therapeutics (SMMT): Landmark Cancer Data, a $10B Binary — We Say HOLD (~$16)
Quarterly earnings-analysis entry for SMMT. Use the links on the right to open the video or podcast episode.